Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Studies suggest that social isolation may exacerbate metabolic dysfunction and impair liver regeneration
WHAT HAPPENS DURING IV THERAPY
Eur J Appl Physiol 2022
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article
